1992
Pharmacology of agents used in bone marrow transplant conditioning regimens
Wiebe V, Smith B, DeGregorio M, Rappeport J. Pharmacology of agents used in bone marrow transplant conditioning regimens. Critical Reviews In Oncology/Hematology 1992, 13: 241-270. PMID: 1476655, DOI: 10.1016/1040-8428(92)90092-5.Peer-Reviewed Original ResearchConceptsBone marrow transplantationTotal body irradiationConditioning regimensPharmacology of agentsSingle fraction total body irradiationTransplant conditioning regimensTransplantation conditioning regimensConditioning regimentEffective immunosuppressionTBI regimensBody irradiationMarrow transplantationCurative potentialEngraftment rateDonor histocompatibilityToxicity profilePharmacologic behaviorRegimensAntineoplastic propertiesHematopoietic spaceAntineoplastic activityDisease statesPharmacology
1990
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. Journal Of Clinical Oncology 1990, 8: 648-56. PMID: 2313334, DOI: 10.1200/jco.1990.8.4.648.Peer-Reviewed Original ResearchConceptsAutologous bone marrow transplantationMaximum-tolerated doseBone marrow transplantationRelapsed lymphomaComplete responseMarrow transplantationDose levelsVP-16Refractory Hodgkin's diseaseTreatment-related mortalityDose-finding studyAssessable patientsAcceptable toxicityConditioning regimenInterstitial pneumonitisHodgkin's diseaseResidual diseaseHodgkin's lymphomaPatient populationDisease progressionHigh dosePatientsLymphomaDiseaseCBV